BUZZ-Arrowhead Pharma gains as two brokerages raise PT after Sarepta deal

Reuters11-27 21:27

** Arrowhead Pharmaceuticals' shares rise 6.4% to $22.39, while Sarepta falls ~1% to $129.40 before the bell

** ** On Tuesday, ARWR and SRPT announced agreement to collaborate on clinical and preclinical programs; ARWR will get $500 mln upfront and $325 mln equity investment from SRPT

** Jefferies and Leerink Partners raise their PTs on ARWR, say that the licensing deal with SRPT resolves cash issues for Arrowhead and allows it to focus on developing cardiometabolic therapies

** Jefferies says deal extends ARWR's cash runway into 2028, giving it sufficient resources for launching plozasiran, which treats a rare metabolic disorder; raises PT by $2 to $67

** Leerink raises PT to $23 from $20 to reflect easing balance sheet concerns, says investors will closely watch ARWR's development milestones

** Ten of 15 brokerages rate the stock "buy" or higher, 5 rate it "hold"; their median PT is $45.50

** As of last close, ARWR down ~31.2% and SRPT up 35% YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment